Trial Profile

A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APX 3330 (Primary)
Indications Bladder cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Solid tumours
Focus Adverse reactions
Sponsors Apexian Pharmaceuticals

Most Recent Events

01 Nov 2021 According to an Ocuphire Pharma media release, data from this trial will be presented at the upcoming American Academy of Ophthalmology (AAO) 2021 annual meeting.
01 Oct 2021 According to an Ocuphire Pharma media release, data from this trial was accepted for podium presentation and discussion at the 39th Annual Meeting of the American Society of Retina Specialists (ASRS).
03 Sep 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com